Trial · NCT00588523
Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
NCT00588523, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2023-10-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma. Trials, record NCT00588523. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00588523
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
- NCT number
- NCT00588523
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 60 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- CNS Cancer, CNS BRAIN
- Interventions
- temozolomide followed by high dose busulfan and thiotepa
- First posted
- 2008-01-08
- Last updated
- 2023-10-27
- Results first posted
- 2023-10-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progession Free Survival | 2 years | To determine the duration of disease control of newly diagnosed pure and mixed anaplastic oligodendrogliomas treated with dose-intensive chemotherapy requiring hematopoietic stem cell support. |
| Secondary | Number of Participants Evaluated for Toxicities | up to 2 years |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progession Free Survival | 2 years | % of participants without progression | NUMBER | |
| SECONDARY | Number of Participants Evaluated for Toxicities | up to 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progession Free Survival | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 85.7 | 95% Confidence Interval 62 to 95.2 | % of participants without progression | |
| Number of Participants Evaluated for Toxicities | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 60 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 60 | |
| Overall Study | COMPLETED | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 57 | |
| Overall Study | NOT COMPLETED | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 3 |
Source ClinicalTrials.gov
Adverse events66
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Platelets | Investigations | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 16 | 60 | |
| other | Leukocytes | Investigations | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 16 | 60 | |
| other | Neutrophils | Investigations | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 13 | 60 | |
| other | Fatigue | General disorders | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 12 | 60 | |
| other | Hemoglobin | Investigations | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 10 | 60 | |
| other | Nausea | Gastrointestinal disorders | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 17 | 60 | |
| other | Platelets | Investigations | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 8 | 60 | |
| other | Constipation | Gastrointestinal disorders | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 6 | 60 | |
| other | Fatigue | General disorders | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 6 | 60 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 10 | 60 |
1 to 10 of 66Source ClinicalTrials.gov
See all 66 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 30 | 60 |
| Total, other adverse events | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 57 | 60 |
| Total, serious adverse events | Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 26 | 60 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28472509 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00588523
GET https://conductscience.org/api/trials/v1/NCT00588523/events?page=2